Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
Top Cited Papers
- 4 September 2009
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 374 (9691), 695-703
- https://doi.org/10.1016/s0140-6736(09)61252-6
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseThe New England Journal of Medicine, 2008
- COPD: what is the unmet need?British Journal of Pharmacology, 2008
- PDE4 inhibitors: current statusBritish Journal of Pharmacology, 2008
- Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax, 2007
- Systemic inflammation and mortality in chronic obstructive pulmonary diseaseThis paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.Canadian Journal of Physiology and Pharmacology, 2007
- Are phosphodiesterase 4 inhibitors just more theophylline?Journal of Allergy and Clinical Immunology, 2006
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary diseaseEuropean Respiratory Journal, 2003
- Inhibition of Inflammation and Remodeling by Roflumilast and Dexamethasone in Murine Chronic AsthmaThe Journal of pharmacology and experimental therapeutics, 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003